Welcome to our dedicated page for Pharming Group N.V. SEC filings (Ticker: PHAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharming Group N.V. SEC filings document a foreign private issuer commercializing rare-disease medicines and reporting through Form 6-K current reports and Form 20-F annual disclosures. The filings cover financial results, revenue trends for RUCONEST® and Joenja® (leniolisib), regulatory developments for APDS, and clinical-program disclosures involving primary immunodeficiencies with immune dysregulation and napazimone (KL1333) in primary mitochondrial disease.
The company's regulatory record also includes annual-report filings, shareholder-meeting materials, auditor appointment matters, remuneration policy proposals, and authorizations related to share issuance and repurchases. These disclosures frame Pharming's governance, capital structure, commercial products, pipeline spending, licensing obligations, and rare-disease development risks.
Pharming Group announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The release states Mr. Lynard has over 20 years of global finance leadership in life sciences, including recent CFO roles at Schoeller Allibert and Zentiva and senior finance roles at Gilead Sciences where he served as Senior Vice President and CFO for Global Commercial Operations, R&D and Manufacturing.
The company frames the hire as strengthening financial leadership following strong first half 2025 financial results and supporting Pharming's growth strategy and commercial and pipeline catalysts. Mr. Lynard holds an MSc in Business Economics and Auditing and an executive MBA from IMD.